Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children
A birth cohort design was used to understand whether heterotypic ligand-blocking norovirus antibodies provide cross-protection within the GII genogroup. We found that almost one-half of children who experienced a norovirus GII episode had preexisting antibodies heterotypic to the infecting genotype; therefore, these antibodies did not provide cross-protection.
Authors
- N.A. Vielot
- M. Diez-Valcarce
- Michael L. Mallory
- J. Vinjé
- Y. Reyes
- R.S. Baric
- Paul D. Brewer-Jensen (ORCID: https://orcid.org/0000-0003-0965-8477)
- S. Becker-Dreps
- L.C. Lindesmith
- F. Bucardo
- Farley Gonzalez
- L. Gutiérrez (ORCID: https://orcid.org/0000-0002-4161-2711)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2024-10-02
- DOI
- https://doi.org/10.17615/nwkn-c072
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Fogarty International Center